News 
Contact Us
No. 18, Fuyuan Road, Tianjin Wuqing Development Area, China
Huge! “Xuebijing” Injection of Chase Sun Continues to Be Introduced into COVID-19 Diagnosis and Treatment Protocol
On March 15,The Ninth Edition of the Country\'s COVID-19 Diagnosis and Treatment Protocol,released by the National Health Commission,was distributed around China for information and guidance.“Xuebijing”Injection of Tianjin Chase Sun Pharmaceutical Co.LTD.(hereinafter referred to as Chase Sun)in Wuqing Development Area continued to be introduced as the recommended dosage for confirmed cases in severe and critical condition during clinical treatment period by latest protocol edition.
It is learned that the latest Protocol is based on deep research on Delta and Omicron variant characteristics of dissemination and confirmed cases,as well as on an in-depth analysis of relevant research findings.Compared with the former Protocol,the latest edition has major updates on testing,regulation and treatment.
“Xuebijing”Injection is the second-grade new medicine of TCM with independent intellectual property rights and exclusive production by Chase Sun.It was selected in a Chinese Plan,“Three Medicines and Three Prescriptions”and continued to be introduced in the Country\'s COVID-19 Diagnosis and Treatment Protocol(from the forth to eight edition).According to a key project,led by academician Zhong Nanshan and other experts,it showed that on the basis of regular treatment,the addition of“Xuebijing”Injection can raise the efficiency of restraining the inflammation response to 91%.Moreover,according to the data from Chinese Critical Care Medicine,an authority journal on critical care,“Xuebijing”Injection can raise the cure rate of severe case in 28 days by 44.5%,decrease the death rate by 9.8%,with no raise on drug safety risk.
Chase Sun continually aims to the research and treatment of sepsis.Except for“Xuebijing”Injection,KB,a first-grade new medicine under study,was the only chemistry medicine that entered the Phase-II of clinical test in domestic sepsis treatment field,and also acquired the clinical notification of Phase-II and Fast Track Qualification of FDA.IMMH-010,a first-grade new medicine,was the first approved oral PD-L1 small-molecule inhibitor in domestic clinical test,which was selected in the key national technology projects of“Major New Drug Development”.In the future,Chase Sun may continually focus on the difficult and critical cases.With the increase in research and development,the introduction of scientific talents and equipment,measures of digital empowerment,as well as the improvement of scientific research level,more contributions and development can be made in critical care medicine field.
Source：
Release Time：2022-04-15 21:49:56
Home